JP2002519318A5 - - Google Patents

Download PDF

Info

Publication number
JP2002519318A5
JP2002519318A5 JP2000556766A JP2000556766A JP2002519318A5 JP 2002519318 A5 JP2002519318 A5 JP 2002519318A5 JP 2000556766 A JP2000556766 A JP 2000556766A JP 2000556766 A JP2000556766 A JP 2000556766A JP 2002519318 A5 JP2002519318 A5 JP 2002519318A5
Authority
JP
Japan
Prior art keywords
corticosteroid
weight
surfactant component
high hlb
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000556766A
Other languages
English (en)
Japanese (ja)
Other versions
JP4875239B2 (ja
JP2002519318A (ja
Filing date
Publication date
Priority claimed from US09/105,838 external-priority patent/US6241969B1/en
Application filed filed Critical
Publication of JP2002519318A publication Critical patent/JP2002519318A/ja
Publication of JP2002519318A5 publication Critical patent/JP2002519318A5/ja
Application granted granted Critical
Publication of JP4875239B2 publication Critical patent/JP4875239B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000556766A 1998-06-26 1999-06-24 鼻および肺送達のためのコルチコステロイドを含有する水性組成物 Expired - Fee Related JP4875239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/105,838 US6241969B1 (en) 1998-06-26 1998-06-26 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US09/105,838 1998-06-26
PCT/US1999/014351 WO2000000181A1 (en) 1998-06-26 1999-06-24 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery

Publications (3)

Publication Number Publication Date
JP2002519318A JP2002519318A (ja) 2002-07-02
JP2002519318A5 true JP2002519318A5 (enExample) 2006-08-17
JP4875239B2 JP4875239B2 (ja) 2012-02-15

Family

ID=22308060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000556766A Expired - Fee Related JP4875239B2 (ja) 1998-06-26 1999-06-24 鼻および肺送達のためのコルチコステロイドを含有する水性組成物

Country Status (8)

Country Link
US (1) US6241969B1 (enExample)
EP (1) EP1089715B8 (enExample)
JP (1) JP4875239B2 (enExample)
AT (1) ATE311174T1 (enExample)
AU (1) AU4717199A (enExample)
CA (1) CA2335900C (enExample)
DE (1) DE69928665T2 (enExample)
WO (1) WO2000000181A1 (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
EP1143930B8 (en) * 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
US7029656B2 (en) * 1999-12-23 2006-04-18 Coifman Robert E Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HRP20021025B1 (hr) * 2000-05-22 2013-11-22 Chiesi Farmaceutici S.P.A. Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030064052A1 (en) * 2001-05-21 2003-04-03 Ponwell Enterprises, Ltd. Compositions for protein delivery via the pulmonary route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
CA2447519C (en) * 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003057188A1 (en) * 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
DE60302454T2 (de) * 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003100333A2 (en) * 2002-05-21 2003-12-04 University Of Massachusetts Low pressure impact separator for separation, classification and collection of ultra­fine particles
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004004640A2 (en) * 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
WO2004047841A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US8288372B2 (en) * 2002-11-26 2012-10-16 Alexza Pharmaceuticals, Inc. Method for treating headache with loxapine
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
AU2003293833B2 (en) * 2002-12-12 2009-10-01 Covis Pharma B.V. Combination medicament
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
BRPI0408925A (pt) * 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20050079166A1 (en) 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
CN1976679B (zh) 2003-12-31 2011-08-31 锡德克斯药物公司 含有磺基烷基醚环糊精以及皮质甾类的吸入制剂
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1730751B1 (en) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
DE602005026225D1 (de) * 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
WO2005102354A1 (en) * 2004-04-20 2005-11-03 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2576961A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US8277780B2 (en) * 2005-05-27 2012-10-02 Taro Pharmaceutical North America, Inc. Stable liquid desoximethasone compositions with reduced oxidized impurity
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP1988878A2 (en) * 2006-02-15 2008-11-12 Tika Läkemedel AB Sterilization of corticosteroids with reduced mass loss
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
FR2916974B1 (fr) * 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
LT3354276T (lt) * 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
SG172885A1 (en) 2009-01-23 2011-08-29 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
EP2366408B1 (en) * 2010-03-01 2012-07-18 Laboratorios SALVAT, S.A. Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US11986491B2 (en) * 2011-06-22 2024-05-21 Iview Therapeutics, Inc. Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
EP3003272A1 (en) * 2013-06-03 2016-04-13 Tolmar, Inc. Corticosteroid compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
WO2015109201A1 (en) 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
CA3147444A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN114642677A (zh) * 2020-12-21 2022-06-21 上海凯屹医药科技有限公司 一种稳定的含有苦丁皂苷类化合物的液体药物组合物
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US5208226A (en) 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
CA2108266C (en) 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
EP1092430B1 (en) 1991-06-10 2003-08-06 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5314207A (en) 1992-06-10 1994-05-24 Roadmaster Corporation Bicycle with simulated motorcycle parts
ATE191641T1 (de) 1992-08-28 2000-04-15 Pharmos Corp Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
JPH09157157A (ja) * 1995-12-01 1997-06-17 Pola Chem Ind Inc 医薬組成物
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Similar Documents

Publication Publication Date Title
JP2002519318A5 (enExample)
AU775588B2 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1671651B1 (en) Synergistic combination of pumafentrine and salmeterol
AU2003291497B2 (en) The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
JP2002538110A5 (enExample)
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
CA2540174A1 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
WO2007014673A2 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
IL271132B1 (en) Dry powder aclidinium salt pharmaceutical composition for treatment of copd
CA2425489A1 (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
Nagai et al. Bioadhesive dosage forms for nasal administration
JP2011173929A (ja) 呼吸器官の細菌性疾患の処置
Boobis Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide
JP2003527412A (ja) 安定化された乾燥粉末製剤
WO2010126818A1 (en) Intranasal delivery system for dantrolene
KR20030087072A (ko) 비측 투여를 위한 이미다조트리아지논 함유 조성물
CA2483090A1 (en) Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
PL211574B1 (pl) Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego
AU2003292120B2 (en) New synergistic combination comprising roflumilast and formoterol
JP2002527351A (ja) 気道感染に関連した風邪及びインフルエンザ様症状の予防及び治療用組成物
US4689213A (en) Method and composition for treating bronchospastic airway diseases
JP2004523536A5 (enExample)
WO2001015777A1 (en) Pulmonary-administration of mineral ascorbates